GlassScriptPhysician profile
Martha J Miller
NPI 1538382627
$813.03
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $140.96 | 2021 | |
| Glaxosmithkline, LLC. | $126.55 | 2021 | |
| Abbvie INC. | $124.94 | 2021 | |
| Lilly USA, LLC | $94.10 | 2021 | |
| Amgen INC. | $75.69 | 2021 | |
| Janssen Biotech, INC. | $70.56 | 2021 | |
| Genzyme Corporation | $39.21 | 2021 | |
| Horizon Therapeutics Plc | $34.48 | 2021 | |
| Radius Health, INC. | $29.10 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2021 | |
| Ucb, INC. | $15.19 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.